Reports Q2 revenue $8.8M, consensus $8.12M. “We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption,” said David Fischel, Chairman and CEO. “This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STXS:
- Stereotaxis (STXS) Q2 Earnings Cheat Sheet
- Stereotaxis receives FDA clearance for MAGiC Sweep catheter
- Stereotaxis Announces $12.5M Stock Offering
- Stereotaxis announces $12.5M registered direct offering
- Promising Prospects for Stereotaxis’ MAGiC Catheter: A Buy Rating Reinforced by Strong Efficacy and Safety